Vanguard Group
ADCT icon

Vanguard Group’s ADC Therapeutics ADCT Stock Holding History

Vanguard Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.99M Buy
1,129,587
+535,633
+90% +$2.17M ﹤0.01% 3338
2025
Q3 		$2.38M Buy
593,954
+33,431
+6% +$105K ﹤0.01% 3526
2025
Q2 		$1.5M Sell
560,523
-91,484
-14% -$192K ﹤0.01% 3628
2025
Q1 		$919K Buy
652,007
+7,389
+1% +$12.6K ﹤0.01% 3738
2024
Q4 		$1.28M Buy
644,618
+105,259
+20% +$275K ﹤0.01% 3687
2024
Q3 		$1.7M Buy
539,359
+135,130
+33% +$426K ﹤0.01% 3605
2024
Q2 		$1.28M Buy
+404,229
New +$1.61M ﹤0.01% 3712

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group's ADCT Position: Q4 2025 in Review

Vanguard Group increased its ADC Therapeutics (ADCT) stake by 90% in Q4 2025, buying an estimated $2.17M and bringing the position to 1,129,587 shares worth $3.99M. The position accounts for ﹤0.01% of the portfolio, ranked #3338.

Vanguard Group first reported a position in ADCT in Q2 2024 and has held it in 7 quarters since. 115 funds tracked by Wall St. Rank hold ADCT as of Q4 2025.

  • Vanguard Group held 1,129,587 shares of ADC Therapeutics worth $3.99M as of Q4 2025.
  • Vanguard Group bought 535,633 ADC Therapeutics shares in Q4 2025, an estimated $2.17M.
  • ADC Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3338 holding.
  • Vanguard Group first reported a position in ADC Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 115 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.